"The time taken to establish the correct diagnosis is on average about 14 months."
"I have two little children and they deserve a good life and a caring mother. That thought gives me strength."
"We really wish COVID-19 patients would come to the hospital sooner."
AOP Health presents final results from its CONTINUATION-PV study -up to 7.5 years treatment with BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera patients - at EHA 2022 Annual Meeting13. 6. 2022
AOP Health Submits New Drug Application for Landiolol, Seeking Approval in the United States2. 6. 2022
AOP Health opens its Italian base in Pisa20. 5. 2022
Meet Us Globally
World Orphan Drug CongressBoston
Bio-Europe 2022Leipzig, DE
Meet Us in Italy
AOP Health team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease and critical care portfolio and enables to approach patients beyond company’s core markets in Europe.
AOP Health team develops and investigates therapy options for patients with rare diseases and in critical conditions – commitment and appreciation are the essence of our cooperative work.
"AOP Health is unconditionally committed to bringing not only drugs but full treatment support to patients with rare diseases and in critical care."
"AOP Health having international expertise in pharmaceutical and clinical development as well as distribution and marketing of drugs in the rare disease area offers flexible solutions for in- and out-licensing partnerships."
"As a company, we are small enough to be really close to our patients, yet we are large enough to be able to provide them high-quality, personalized customer care."